



Academic Directorate of Communicable
Diseases and Specialised Medicine



Please speak to your health care professional if you are interested in any of the trials listed below or contact the directorate research coordinator Sarah Birch sarah.birch15@nhs.net or 0114 2713696

Haemato-oncolgy Research

Myeloma

Title	Local PI	Description	Link
MUK 9b	Dr Chantry	MUK9 b- Optimum Treatment Protocol: A phase 2 study evaluating optimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia	https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-new-combination-treatment-newly-diagnosed-high-risk-myeloma-plasma-cell-leukaemia-muk-9-b-optimum
CANOVA	Dr Chantry	A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma	https://clinicaltrials.gov/ct2/show/NCT03539744
MUK12	Dr Chantry	A randomised phase II trial of Selinexor, cyclophosphamide and prednisolone vs cyclophosphamide	http://www.isrctn.com/ISRCTN15028850

		and prednisolone in relapsed or refractory multiple myeloma (RRMM) patients	
RUDY	Dr Chantry	A study to determine a detailed phenotype of patients with rare diseases.	https://research.ndorms.ox.ac.uk/rudy/
LoccMMotion	Dr Chantry	A prospective, multicenter study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma who received at least 3 prior lines of therapy.	https://clinicaltrials.gov/ct2/show/NCT04035226
Bone Pain in Multiple Myeloma	Dr Chantry	The main objective of the study to provide an in depth analysis of the pain experienced by the patients, assessing its location, intensity, nature (e.g. neuropathic component), as well as its effect on quality of life, depression and psychological welfare.	
Myeloma XII	Professor Snowden	Accord Myeloma XII: A phase 3 study to determine the role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell	https://www.myeloma.org.uk/documents/myeloma-xii-accord/

		transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma.	
--	--	---	--

Lymphoma, ALL

Title	Local PI	Description	Link
UKALL 14	Dr Morley	A randomized trial for adults with newly diagnosed acute lymphoblastic leukemia	https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/ukall14/
FLAIR	Dr Morley	This trial is to compare the effect on progression-free survival (PFS) of ibrutinib plus rituximab (IR) with that of fludarabine, cyclophosphamide and rituximab (FCR) in patients with previously untreated chronic lymphocytic leukaemia.	https://www.cancerrsearchuk.org/about-cancer/find-a-clinical-trial/a-trial-ibrutinib-rituximab-chronic-lymphocytic-leukaemia-flair
ENRICH	Dr Morley	Multicentre, open label, integrated phase II/III randomised controlled study in untreated patients with mantle cell lymphoma who are considered unsuitable for stem cell transplant.	https://www.cancerrsearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-ibrutinib-for-older-people-with-mantle-cell-lymphoma-enrich
EuroNet	Dr Morley	The EuroNet-PHL-C2 trial is an international, multicentre,	https://www.cancerrsearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-treatment-for-nodular-l

		randomised controlled trial for the first line treatment of a classical Hodgkin`s Lymphoma in children and adolescents	lymphocyte-predominant-hodgkins-lymphoma-children-and-young-people-euroneuro-phl-lp1
PETReA	Dr Morley	PETReA is a non-blinded phase 3 RCT in which all patients receive initial treatment with rituximab (R) plus chemotherapy and are then separated into two groups based on their response as determined by contrast-enhanced CT (ceCT) to assess anatomical response and FDG PET to assess metabolic response.	https://lymphoma-action.org.uk/trial/petrea-phase-3-trial-testing-whether-pet-scans-can-help-make-treatment-decisions-people-0
SeluDex	Dr Morley	International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia	https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-selumetinib-and-dexamethasone-for-acute-lymphoblastic-leukaemia-seludex
ANIMATE	Dr Morley	ANIMATE Study: A phase 2 study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin	https://clinicaltrials.gov/ct2/show/NCT03337919

		lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or second line salvage therapy	
Citadel 203	Dr Morley	A phase II study in relapsed or refractory follicular lymphoma	https://clinicaltrials.gov/ct2/show/NCT03126019
Citadel 205	Dr Morley	A phase II study in relapsed or refractory mantle cell lymphoma	https://lymphoma-action.org.uk/trial/citadel-205-phase-2-trial-testing-incb050465-people-mantle-cell-lymphoma-who-have-had
Tidal	Dr Wright	A phase II study in relapsed or refractory follicular lymphoma	https://clinicaltrials.gov/ct2/show/NCT03768505

AML / MDS

Title	Local PI	Description	Link
AML19	Dr Kaur	A study to compare induction chemotherapy schedules in AML	https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-different-treatments-for-acute-myeloid-leukaemia-and-high-risk-myelodysplastic
LACEWING	Dr Kaur	A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of	https://clinicaltrials.gov/ct2/show/NCT02927262

		ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy.	
--	--	---	--

Sickle Cell

Title	Local PI	Description	Link
STAND	Dr Wright	Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients	https://clinicaltrials.gov/ct2/show/NCT03814746

GVHD

Title	Local PI	Description	Link
HERACLES	Professor Snowden	Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disease after Allogeneic hematopoietic stem cell transplantation with fecal microbiota transfer (HERACLES STUDY).	https://clinicaltrials.gov/ct2/show/NCT03359980
GRAPHITE	Dr Kaur	A Randomised, Double Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host	https://clinicaltrials.gov/ct2/show/NCT03657160

		Disease in Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation.	
--	--	---	--

CML

Title	Local PI	Description	Link
CALLS	Dr Francis	A Cohort Study To Establish the Prevalence of Mutations in Patients With CML Who Meet the ELN Criteria for Warning or Failure and Patients With Ph+ ALL With Detectable BCR-ABL Currently Being Treated With First or Subsequent TKI Therapy in the UK Using Next-Generation Sequencing	https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/calls-cml-and-all-low-level-mutation-study/

Last updated 08/11/2019